Codes and Coverage

Supporting patient access

BMS Access Support® may help support patient access by conducting benefits reviews and offering prior authorization and appeals process assistance for enrolled patients. Additionally, the information below provides product-specific billing and diagnosis codes, reimbursement and coding guides, distribution information, and additional coverage support offerings. To view available coding and coverage information, please select your patient’s prescribed medication.

Additional eligibility criteria and terms may apply. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

YERVOY®

(ipilimumab)

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Explore codes on this page:      ⬇HCPCS      ⬇CPT      ⬇NDC      ⬇ICD-10

Healthcare Common Procedure Coding System (HCPCS) Codes1

Issued by CMS

J9228 Injection, ipilimumab, 1 mg

Providers and suppliers are required to report the JW modifier on Part B drug claims for discarded drugs and biologicals. Also, providers and suppliers must document the amount of discarded drugs or biologicals in Medicare beneficiaries’ medical records.2

Current Procedural Terminology (CPT)3,†
96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415 Chemotherapy administration, IV infusion; each additional hour
  • List separately in addition to code for primary procedures
  • Use 96415 in conjunction with 96413
  • Report 96415 for infusion intervals of greater than 30 minutes beyond 1-hour increments
National Drug Codes (NDC)4

Issued by the FDA

Note: The NDCs for YERVOY, shown here, are often necessary in addition to the appropriate J- or C-code when filing a claim for reimbursement.

00003-2327-11 One 50 mg/10 mL (5 mg/mL), single-dose vial
00003-2328-22 One 200 mg/40 mL (5 mg/mL), single-dose vial
International Classification of Diseases, Tenth Revision, Clinical Modification Diagnosis Codes (ICD-10-CM)5
C43 Malignant melanoma of skin
C43.0 Malignant melanoma of lip
C43.1 Malignant melanoma of eyelid, including canthus
C43.10 Malignant melanoma of unspecified eyelid, including canthus
C43.11 Malignant melanoma of right eyelid, including canthus
C43.111 Malignant melanoma of right upper eyelid, including canthus
C43.112 Malignant melanoma of right lower eyelid, including canthus
C43.12 Malignant melanoma of left eyelid, including canthus
C43.121 Malignant melanoma of left upper eyelid, including canthus
C43.122 Malignant melanoma of left lower eyelid, including canthus
C43.2 Malignant melanoma of ear and external auricular canal
C43.20 Malignant melanoma of unspecified ear and external auricular canal
C43.21 Malignant melanoma of right ear and external auricular canal
C43.22 Malignant melanoma of left ear and external auricular canal
C43.3 Malignant melanoma of other and unspecified parts of face
C43.30 Malignant melanoma of unspecified part of face
C43.31 Malignant melanoma of nose
C43.39 Malignant melanoma of other parts of face
C43.4 Malignant melanoma of scalp and neck
C43.5 Malignant melanoma of trunk
C43.51 Malignant melanoma of anal skin
C43.52 Malignant melanoma of skin of breast
C43.59 Malignant melanoma of other part of trunk
C43.6 Malignant melanoma of upper limb, including shoulder
C43.60 Malignant melanoma of unspecified upper limb, including shoulder
C43.61 Malignant melanoma of right upper limb, including shoulder
C43.62 Malignant melanoma of left upper limb, including shoulder
C43.7 Malignant melanoma of lower limb, including hip
C43.70 Malignant melanoma of unspecified lower limb, including hip
C43.71 Malignant melanoma of right lower limb, including hip
C43.72 Malignant melanoma of left lower limb, including hip
C43.8 Malignant melanoma of overlapping sites of skin
C43.9 Malignant melanoma of skin, unspecified
C21 Malignant neoplasm of anus and anal canal
C21.0 Malignant neoplasm of anus, unspecified
C21.1 Malignant neoplasm of anal canal
C51 Malignant neoplasm of vulva
C51.0 Malignant neoplasm of labium majus
C51.1 Malignant neoplasm of labium minus
C51.2 Malignant neoplasm of clitoris
C51.9 Malignant neoplasm of vulva, unspecified
C52 Malignant neoplasm of vagina
C57 Malignant neoplasm of other and unspecified female genital organs
C57.7 Malignant neoplasm of other specified female genital organs
C57.8 Malignant neoplasm of overlapping sites of female genital organs
C57.9 Malignant neoplasm of female genital organ, unspecified
C60 Malignant neoplasm of penis
C60.0 Malignant neoplasm of prepuce
C60.1 Malignant neoplasm of glans penis
C60.8 Malignant neoplasm of overlapping sites of penis
C60.9 Malignant neoplasm of penis, unspecified
C63 Malignant neoplasm of other and unspecified male genital organs
C63.0 Malignant neoplasm of epididymis
C63.00 Malignant neoplasm of unspecified epididymis
C63.01 Malignant neoplasm of right epididymis
C63.02 Malignant neoplasm of left epididymis
C63.1 Malignant neoplasm of spermatic cord
C63.10 Malignant neoplasm of unspecified spermatic cord
C63.11 Malignant neoplasm of right spermatic cord
C63.12 Malignant neoplasm of left spermatic cord
C63.2 Malignant neoplasm of scrotum
C63.7 Malignant neoplasm of other specified male genital organs
C63.8 Malignant neoplasm of overlapping sites of male genital organs
C63.9 Malignant neoplasm of male genital organ, unspecified
Z51.12 Encounter for antineoplastic immunotherapy (only)

If infusion for antineoplastic immunotherapy is the only reason for the patient encounter, physicians and hospitals may report ICD-10-CM code “Z51.12 Encounter for antineoplastic immunotherapy” as the primary diagnosis.

Coding for YERVOY is dependent on the insurer and the care setting in which the drug will be administered. Oncology practices need to make coding decisions based on the diagnosis and treatment of each patient and the specific insurer requirements.

Please see U.S. Full Prescribing Information for YERVOY.

*Healthcare providers should code healthcare claims based upon the service that is rendered, the patient’s medical record, the coding requirements of each health insurer, and best coding practices. Coding guidance provided under this heading does not provide a guarantee of reimbursement and should be considered together with all applicable coding guidance and standards. All of the coding information presented by this website is applicable to outpatient procedures only.

CPT codes and descriptions only are ©2023 by American Medical Association (AMA). All rights reserved. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association.

This is a category code and is invalid for stand-alone use.

References:

  1. American Medical Association. 2020 HCPCS Level II. Professional ed. Chicago, IL: American Medical Association; 2020.
  2. Centers for Medicare & Medicaid Services. MLN Matters, Number MM9603 Revised. https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/MM9603.pdf. Revised June 10, 2016. Accessed August 2, 2023.
  3. American Medical Association. Current Procedural Terminology 2019. Professional ed. Chicago, IL: American Medical Association; 2018.
  4. YERVOY (ipilimumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
  5. Centers for Medicare & Medicaid Services. ICD-10-CM tabular list of diseases and injuries. https://www.cms.gov/medicare/coding-billing/icd-10-codes/2023-icd-10-cm. Accessed August 2, 2023.

YERVOY may be purchased through the distributors listed below.

Physician Offices

For offices that prefer to use the services of a specialty pharmacy, specialty pharmacies can obtain YERVOY from the distributors listed above.

Hospitals and Infusion Centers
Puerto Rico Hospitals and Clinics

Above information is accurate as of 01/26.

The YERVOY distribution program includes extended payment terms to Bristol Myers Squibb authorized YERVOY distributors. Healthcare providers and institutions should contact their YERVOY distributor to understand specific payment terms that may be available to them from their distributor.

Please see U.S. Full Prescribing Information for YERVOY.

FDA Approval Letters as Posted by the FDA:

For the adjuvant treatment of fully resected stage III melanoma (lymph node >1 mm)

For the treatment of unresectable or metastatic melanoma to include pediatric patients (12 years and older)

For the treatment of unresectable or metastatic melanoma in adults

Claim Forms for Outpatient Administration

Blank CMS-1500
Physician Office

Blank UB-04/CMS-1450
Hospital Outpatient

See Payer Policy Details

Learn about payer information by state for applicable treatments.